A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Experimental: Repotrectinib (TPX-0005)

Phase 1 Oral repotrectinib (TPX-0005) + cocktail drugs (metformin hydrochloride, digoxin, rosuvastatin calcium)

Drug: TPX-0005

Oral TPX-0005 capsules

Other Name: repotrectinib

Drug: Metformin Hydrochloride

oral solution

Other Names:

  • Glucophage
  • Metabet
  • Glucient
  • Diagemet
  • Axpinet

Drug: Digoxin

oral tablet

Other Name: Lanoxin

Drug: Rosuvastatin Calcium

oral tablet

Other Name: Crestor

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 1, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments